How to Check if a GLP-1 Is FDA-Approved

Start with the exact product identity

FDA approval is not a broad category attached to every GLP-1 search term. It attaches to a specific product, dosage form, active ingredient, application, and approved use. A brand name, generic ingredient, tablet, injection, and investigational code can point to different source records.

That distinction matters for GLP-1 pages because many searches mix brand names, ingredient names, research codes, compounded-product claims, and trial headlines. Before relying on a summary, identify the product name, active ingredient, dosage form, and the specific use being discussed.

Use FDA approval databases for approval status

FDA approval and database resources are the authoritative starting point for approved-drug status. FDA lists resources such as Drugs@FDA, Drug Trials Snapshots, and the Orange Book from its drug approvals and databases page. Those sources answer different questions, so a clean source check keeps them separate.

Drugs@FDA and related FDA approval resources can show whether a product has an approval record, approval history, or labeling information. The Orange Book is useful for approved drug products and therapeutic-equivalence information. Neither source turns a similar-sounding product, research chemical, or compounded claim into an approved medicine.

Read the label source for the exact medicine

DailyMed is a government labeling database from the National Library of Medicine that includes labeling submitted to FDA. It is useful for confirming a product label, but the exact match matters. A label for one brand, dosage form, or active ingredient does not automatically apply to another product.

This page does not reproduce dose schedules, administration steps, contraindications, or side-effect instructions from labels. Product labels can be detailed, and individual interpretation belongs with a licensed clinician or pharmacist who can connect the exact prescription to the current label.

Treat clinical trials as research records

ClinicalTrials.gov records describe clinical studies. They can show a study title, sponsor, recruitment status, design, outcome measures, and update dates. That information can be important for understanding research status, but it is not FDA approval and it is not prescribing information.

This difference is especially important for investigational GLP-1 terms. A completed trial, active study, estimated completion date, or sponsor release can explain why a drug candidate is being watched. It does not create an approved U.S. product label.

Check unapproved and compounded-product claims carefully

FDA has published concerns about unapproved GLP-1 drugs used for weight loss. Claims about products marketed as compounded, research-use, peptide, or not-for-human-consumption GLP-1 options need current FDA source checks and careful wording.

A source check can identify whether FDA has approved a product or published concerns about a category. It cannot make an unapproved product appropriate for personal use, and this article does not provide compounded-drug safe-use, sourcing, storage, mixing, dosing, or purchasing guidance.

Use retatrutide as a source-category example

Retatrutide and LY3437943 searches show why source categories matter. A ClinicalTrials.gov record can document a study. A sponsor update can report a company milestone. FDA materials control approval and unapproved-product framing. Those sources answer different questions.

For the current retatrutide answer, use the dedicated retatrutide FDA approval status page. This article explains how to read the source types; it does not replace product-specific retatrutide coverage or provide clinical-use guidance.

Where to check GLP-1 approval and source status

How to Check if a GLP-1 Is FDA-Approved questions